Adjuvant treatment with the MAGE-A3 immunotherapeutic did not increase disease-free survival. Further development of the MAGE-A3 immunotherapeutic for use in NSCLC has been stopped. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.